Abbvie Inc. vs AstraZeneca PLC
ABBV vs AZN — side-by-side comparison from reported financials. ABBV leads 6, AZN leads 6 of 12 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
AstraZeneca PLC
AZN · Healthcare
$159.20+0.26%Solid
| Metric | ABBV | AZN |
|---|---|---|
| Price | $276.43 | $159.20 |
| Market cap | $488B | $247B |
| Revenue (TTM) | $64.4B | $58.7B |
| Revenue growth | +1.8% | +9.8% |
| Net margin | 9.8% | 17.4% |
| Free cash flow | $18.2B | $10.7B |
| Net cash (debt) | ($56.2B) | ($27.4B) |
| 1-year price return | +19.8% | -6.4% |
| P/E | 77.4 | 23.4 |
| P/E vs own history (cheap-side %) | 23% | 65% |
| Dividend yield | 2.45% | 2.01% |
| Return on equity | 96% | 22% |
| Altman Z-score | 2.33 | 2.16 |
| CV checks passed | 9 of 11 | 11 of 11 |
| Employees | 57,000 | 96,100 |
Full résumé-style profiles: ABBV CV · AZN CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.